Tenzing Partners acted as exclusive sell-side M&A advisor to the shareholders of OrganoTherapeutics SARL on its sale to Transpharmation, a UK/Canada-based preclinical contract research organisation (CRO) specialised in neuroscience.
The acquisition allows Transpharmation to add human-relevant in vitro organoid models to its in vivo neuroscience pharmacology capabilities, offering drug developers both approaches through a single partner. OrganoTherapeutics continues to operate as a subsidiary of Transpharmation.
Tenzing advised the founders throughout the process, adding a new cross-border transaction to its track record: Luxembourg seller, UK/Canada buyer.